With Trump’s Return, Pharma Trades Disagreeable Knowns For Uncertainty

 
• By Jessica Merrill
  
FDA and HHS leadership could be a concern for pharma when Donald Trump returns to the White House. (Shutterstock)

More from Elections

More from Legislation